Aug 2026· Basic Research in Cardiology· Vol 121, pp. 837 - 862· 0 citations· 60 references
Medicine
TL;DR
It is reported that p38α deficiency attenuates ferroptosis and protects against myocardial I/R injury by stabilizing c-Myc, and the p38α/c-Myc/NCOA4 axis is nominated as a potential therapeutic target in myocardial I/R injury.
Abstract
Myocardial ischemia/reperfusion (I/R) injury constitutes a major clinical challenge in ischemic heart disease, and ferroptosis has been recognized as a core driver of cardiomyocyte death during reperfusion. However, the upstream regulatory network governing myocardial ferroptosis remains incompletely defined. The mitogen-activated protein kinase 14 (p38α, MAPK14) is a stress-activated kinase critically involved in cardiac pathophysiology, yet its role in I/R-induced ferroptosis remains unclear. Here, we report that p38α deficiency attenuates ferroptosis and protects against myocardial I/R injury by stabilizing c-Myc. Phosphorylated p38α (p-p38α) was significantly elevated in mouse hearts after I/R and in cardiomyocytes following oxygen–glucose deprivation/reperfusion (OGD/R). Cardiomyocyte-specific p38α knockout markedly reduced ferroptosis, myocardial infarct size, and cardiac dysfunction. Mechanistically, p-p38α interacts with c-Myc under I/R stress via key residues Arg291, Arg300, and Lys304 of c-Myc and promotes the recruitment of the E3 ubiquitin ligase STUB1, thereby enhancing ubiquitination at Lys51 (K51) of c-Myc and its proteasomal degradation. Loss of p38α stabilizes c-Myc protein and reverses this process. Furthermore, c-Myc acts as a transcriptional repressor of NCOA4, a core mediator of ferroptosis. I/R-induced downregulation of c-Myc relieves NCOA4 suppression, triggering iron overload, lipid peroxidation, and ferroptosis. Overexpression of c-Myc or inhibition of STUB1 or NCOA4 abolished the pro-ferroptotic effect of I/R. Pretreatment with the p38α inhibitor VX-745 recapitulated the cardioprotective effects by restoring the p38α/c-Myc/NCOA4 axis in vivo. Collectively, our findings identify the p38α/c-Myc/NCOA4 signaling axis as a regulatory cascade governing myocardial I/R-induced ferroptosis. These findings nominate the p38α/c-Myc/NCOA4 axis as a potential therapeutic target in myocardial I/R injury.
Myocardial ischemia-reperfusion (I/R) injury remains a leading cause of cardiac dysfunction and mortality worldwide. Serine/arginine-Rich Protein Kinase 3 (SRPK3) is highly expressed in cardiac muscle, yet its specific pathological role in I/R injury has not been fully characterized. In this study, we utilized cardiac-...
Yun Xing, Saiyang Xie, Nan Zhao et al.· Acta Pharmacologica Sinica· 0 citations
OBJECTIVES
Myocardial ischemia-reperfusion (I/R) injury is a major cause of ischemic cardiomyopathy and chronic heart failure, underscoring the need for new cardioprotective strategies. ATP synthase inhibitory factor 1 (IF1) maintains mitochondrial function and limits oxidative damage during I/R injury. Our previous wo...
Beiduo Tian, Yao Dong, Chenlu Yuan et al.· International Immunopharmaco...· 0 citations
Myocardial ischemia/reperfusion (I/R) injury is closely associated with excessive oxidative stress and ferroptosis. Salidroside (Sal), a major active component of Rhodiola, has demonstrated cardioprotective properties, yet its precise mechanisms in regulating ferroptosis remain unclear. The present study investigated w...
Zhi-Cong Qiu, Jian-Nan Li, Yi-Zhou Li et al.· International Journal of Mol...· 0 citations
Findings identify the NAMPT-FSP1/CoQ10 axis as a potential metabolic target for myocardial protection against reperfusion injury and attenuates MIRI by restoring redox homeostasis and sustaining FSP1/CoQ10-mediated ferroptosis defense, likely through NAD(P)H-dependent metabolic coupling.
Xiao-Dong Wang, Chang Liu, Jie Wang et al.· Life Science· 0 citations
Myocardial ischemia–reperfusion injury (MIRI) remains a major complication in acute coronary syndrome and cardiac surgery, with oxidative stress and metabolic dysregulation serving as central pathogenic drivers. This study aimed to clarify whether the novel MyD88 inhibitor TJ-M2010-5 confers cardioprotection against MI...
Bo Wang, Xia Huang, Lin Xie· International Journal of Mol...· 0 citations
Despite being the initial intervention of choice, revascularization for myocardial ischemia-reperfusion (I/R) injury remains constrained, making the exploration of novel therapeutic targets imperative. Alpha-kinase 1 (ALPK1) knockdown mitigates ischemic brain injury, whereas its function in cardiac I/R injury requires...
Yue Liu, Ruisi Hu, Yan-Teng Wang et al.· Biochemical Pharmacology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.